Immunexpress to Present New Data at the Society of Critical Care Medicine (SCCM) 2025 Critical Care Congress

SEATTLE and BRISBANE, Australia, Feb. 24, 2025 /PRNewswire/ -- Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced its participation, including the presentation of two posters, at the Society of Critical Care Medicine (SCCM) 2025 Critical Care Congress in Orlando, Florida, from February 23 – 25, 2025.

Immunexpress Chief Medical Officer Dr. Roy Davis will present a Research Snapshot entitled, "SeptiCyte RAPID performance is not affected by different sites of primary infection in sepsis," as part of the Research Snapshot Theatre on Monday, February 24, at 9 a.m. ET in RST 08. Data collected from 378 patients across 10 hospitals located in the U.S. and Europe demonstrate the ability of SeptiCyte® RAPID to aid physicians in distinguishing sepsis from systemic inflammatory responses syndrome (SIRS) regardless of the location of the primary infection.

An abstract entitled, "Diagnosing Pediatric Sepsis with SeptiCyte RAPID Host Gene Expression," will be presented as part of the Research Snapshot Theatre on Tuesday, February 25, at 8:45 a.m. ET in RST 08.

The study included descriptive investigations of four patient cohorts at two pediatric hospitals in the U.S. and Australia. The patient cohorts included critically ill pediatric patients between one month and 18 years old who were admitted to the Pediatric Intensive Care Unit (PICU) and were undergoing a septic work-up or exhibiting modified SIRS criteria (U.S. cohort n = 125; Australia cohort n = 159). SeptiCyte® RAPID clinical performance was evaluated by using AUROC comparison to retrospective physician diagnosis with sepsis operationally defined as SIRS with documented or highly suspected infection. SeptiCyte RAPID differentiated sepsis from infection-negative SIRS in critically ill children with good predictive power.  

"This study indicates the potential utility of SeptiCyte RAPID in differentiating between sepsis and SIRS in pediatric populations, particularly in the early stages of sepsis when therapeutic intervention may be most effective," commented Jerry J. Zimmerman, MD, PhD, MCCM, of Seattle Children's – Critical Care.

Additionally, Immunexpress will host an exhibit booth from Sunday, February 23, to Tuesday, February 25. The exhibit booth, #417, will host demonstrations of SeptiCyte® RAPID, discussions of recent study findings, and an interactive "Escape Room" game in which players may test their knowledge of sepsis by virtually diagnosing a patient via their smart phones. Players at the top of the Escape Room game leaderboard will earn prizes, and Immunexpress will provide a donation to the Sepsis Alliance each time the game is played. The Escape Room game may be accessed via a QR code accessible on Immunexpress' social media channels and at the exhibit booth. Exhibition times are listed below:

• Sunday, February 23, from 9:30 a.m. – 3:45 p.m. ET
• Monday, February 24, from 8:45 a.m. – 3:30 p.m. ET
• Tuesday, February 25, from 8:45 a.m. – 1:30 p.m. ET

About SeptiCyte® RAPID

SeptiCyte® RAPID is a sample-to-answer, cartridge-based, host response molecular test for sepsis using reverse transcription polymerase chain reaction (RT-PCR) to quantify the relative expression levels of host response genes isolated from whole blood. SeptiCyte® RAPID is used in conjunction with clinical assessments, vital signs and laboratory findings as an aid to differentiate infection-positive (sepsis) from infection-negative systemic inflammation response syndromes in patients with escalating signs and symptoms of critical illness. SeptiCyte® RAPID generates a score (SeptiScore®) that falls within four discrete interpretation bands based on the increasing likelihood of sepsis. SeptiCyte® RAPID is intended for in-vitro diagnostic use and runs on the Biocartis Idylla™ Platform.

SeptiCyte® RAPID is CE Marked as a near-patient sample-to-answer test in European Union (EU) member countries and those harmonized with the EU IVD Directive (98/79/EC). As of November 2021, SeptiCyte® RAPID has been FDA cleared for use in hospitalized patients suspected of sepsis.

About Immunexpress

Immunexpress is a molecular diagnostic company, based in Brisbane and Seattle, committed to improving outcomes for patients suspected of sepsis. Immunexpress' SeptiCyte® technology can assess a patient's dysregulated immune response by quantifying and analyzing gene expression from whole blood, providing actionable results in about an hour from sepsis suspicion, to guide the physician in optimizing patient management decisions. SeptiCyte® RAPID is a lab test for sepsis that combines SeptiCyte® technology with the ease-of-use of the revolutionary Biocartis' Idylla™ Platform; it supports differentiating infection (bacterial, viral, fungal) positive sepsis that could lead to organ dysfunction and death from patients with less serious infection negative systemic inflammation. This powerful test enhances early sepsis detection and can strongly support its diagnosis in the crucial first hour(s) that determines clinical outcome. SeptiCyte® RAPID also has a high potential to reduce sepsis associated healthcare costs.

For more information, visit and https://immunexpress.com. Follow Immunexpress on Twitter and LinkedIn.

Immunexpress Media Contact: 

Maddie Stabinski
Russo Partners, LLC 
[email protected] 

SOURCE Immunexpress, Inc.